Last Updated : February 24, 2022
Details
FilesProject Status:
Completed
Project Line:
Horizon Scan
Project Sub Line:
Emerging Health Technologies
Project Number:
EH0099-000
This Horizon Scan summarizes the available information regarding emerging targeted therapies for the treatment of generalized myasthenia gravis. Myasthenia gravis is a rare and chronic autoimmune disease in which autoantibodies attack specific proteins in the neuromuscular junction, resulting in muscle weakness. In this scan, we have reviewed 6 new treatment strategies that target specific areas of the immune system involved in the pathogenesis of myasthenia gravis: efgartigimod, rozanolixizumab, zilucoplan, ravulizumab, batoclimab, and nipocalimab.
Files
Last Updated : February 24, 2022